| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1020221540 |
| P356 | DOI | 10.2165/00003495-200363080-00004 |
| P698 | PubMed publication ID | 12662125 |
| P2093 | author name string | Karen L Goa | |
| Risto S Cvetkovic | |||
| P2860 | cites work | Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy | Q74770724 |
| Methadone withdrawal when starting an antiretroviral regimen including nevirapine | Q77353010 | ||
| Hyperlipidemia under treatment with proteinase inhibitors | Q77372902 | ||
| In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification | Q77781583 | ||
| Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction | Q78045189 | ||
| Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience | Q34552023 | ||
| Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients | Q34725556 | ||
| Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. | Q34732938 | ||
| Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations | Q34738805 | ||
| Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection | Q34740804 | ||
| Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. | Q35134071 | ||
| The HIV-1 protease as a therapeutic target for AIDS | Q35898324 | ||
| Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. | Q39551617 | ||
| Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients | Q39606435 | ||
| Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections | Q40806736 | ||
| Comparative pharmacokinetics of antiviral nucleoside analogues | Q40886850 | ||
| Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus | Q40998928 | ||
| Cytochrome P450: new nomenclature and clinical implications | Q41691948 | ||
| Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years | Q43569408 | ||
| ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis. | Q43585066 | ||
| A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors | Q43613003 | ||
| Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. | Q43766805 | ||
| Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients | Q43896562 | ||
| Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. | Q44043469 | ||
| Serious bradyarrhythmia that was possibly induced by lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome | Q44081430 | ||
| Limited penetration of lopinavir into seminal plasma of HIV-1-infected men. | Q44097517 | ||
| Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families | Q44108852 | ||
| Lopinavir | Q44164433 | ||
| Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. | Q44192276 | ||
| Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. | Q44252661 | ||
| The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). | Q44259622 | ||
| Lipodystrophy associated with protease inhibitors | Q44520144 | ||
| Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study | Q44820677 | ||
| Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden | Q45746350 | ||
| HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors | Q46201727 | ||
| Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission | Q48008071 | ||
| The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. | Q50748394 | ||
| The cost effectiveness of combination antiretroviral therapy for HIV disease. | Q52067020 | ||
| Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. | Q54036205 | ||
| Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. | Q54117055 | ||
| New developments in anti-HIV chemotherapy | Q56786460 | ||
| Poor penetration of the male genital tract by HIV-1 protease inhibitors | Q56816804 | ||
| Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex | Q67920575 | ||
| A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection | Q71523437 | ||
| Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers | Q72871970 | ||
| Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? | Q73048910 | ||
| The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals | Q73064639 | ||
| Predictors of optimal virological response to potent antiretroviral therapy | Q73064663 | ||
| Fat distribution and metabolic changes in patients with HIV infection | Q73343740 | ||
| Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir | Q73998577 | ||
| Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults | Q74372670 | ||
| Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection | Q74492643 | ||
| Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy | Q24514773 | ||
| Active human immunodeficiency virus protease is required for viral infectivity | Q24647696 | ||
| Rational design of peptide-based HIV proteinase inhibitors | Q28330897 | ||
| Effect of two novel inhibitors of the human immunodeficiency virus protease on the maturation of the HIV gag and gag-pol polyproteins | Q28331560 | ||
| ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease | Q28369297 | ||
| Prognosis in HIV-1 infection predicted by the quantity of virus in plasma | Q29619980 | ||
| ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. | Q31977860 | ||
| Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir | Q32067953 | ||
| A risk-benefit assessment of HIV protease inhibitors | Q33609283 | ||
| Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone | Q33661055 | ||
| Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1 | Q33700962 | ||
| ABC of Aids: Development of the epidemic | Q33805535 | ||
| Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study | Q33892705 | ||
| Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences | Q33930053 | ||
| HIV protease inhibitor-related lipodystrophy syndrome | Q33946902 | ||
| Use of HIV protease inhibitors as pharmacoenhancers | Q34202867 | ||
| Principles and practice of HIV-protease inhibitor pharmacoenhancement | Q34459378 | ||
| P433 | issue | 8 | |
| P921 | main subject | lopinavir | Q422585 |
| ritonavir | Q422618 | ||
| lopinavir/ritonavir | Q3836750 | ||
| P304 | page(s) | 769-802 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Lopinavir/ritonavir: a review of its use in the management of HIV infection | |
| P478 | volume | 63 |
| Q90156297 | A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2) |
| Q28485518 | A global comparison of the human and T. brucei degradomes gives insights about possible parasite drug targets |
| Q46371595 | A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients |
| Q36250418 | A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study |
| Q34100187 | Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir |
| Q99237635 | Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment? |
| Q90327975 | Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study |
| Q42970314 | Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users |
| Q36104280 | Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance. |
| Q35647173 | CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir |
| Q36538695 | Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742. |
| Q40569235 | Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug |
| Q97644054 | Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen |
| Q35259915 | Current and Novel Inhibitors of HIV Protease |
| Q35564329 | Cytochrome P450 3A and their regulation |
| Q97084237 | Diabetes and COVID-19: Global and Regional Perspectives |
| Q97528635 | Drug targets for COVID-19 therapeutics: Ongoing global efforts |
| Q57180639 | Drug-drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs |
| Q99569581 | Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19 |
| Q35208091 | Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells. |
| Q24816065 | Functional genomic analysis of C. elegans molting |
| Q35252678 | Guidelines for the care of pregnant women living with HIV and interventions to reduce perinatal transmission: executive summary |
| Q35012924 | HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites |
| Q51664168 | Headache attributed to infections nosography and differential diagnosis. |
| Q30359339 | Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014. |
| Q36910151 | Interaction between lopinavir/ritonavir and warfarin |
| Q95644610 | Interactions of recommended COVID-19 drugs with commonly used psychotropics |
| Q98613550 | Investigation on the impacts of COVID-19 quarantine on society and environment: Preventive measures and supportive technologies |
| Q37788210 | Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection |
| Q34652472 | Lopinavir/ritonavir: a review of its use in the management of HIV infection |
| Q34349192 | Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice |
| Q36286228 | Nelfinavir: a review of its use in the management of HIV infection |
| Q96138639 | Novel therapeutic approaches for treatment of COVID-19 |
| Q96577202 | Overview of therapeutic drug research for COVID-19 in China |
| Q42941908 | Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir |
| Q35057007 | P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease. |
| Q34490216 | Pediatric response to second-line antiretroviral therapy in South Africa |
| Q92620161 | Perspectives of healthcare professionals of the neuropsychiatric side effects associated with efavirenz and its management |
| Q36993453 | Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers |
| Q35191590 | Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children |
| Q48101081 | Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas |
| Q41644790 | Plasma and Intracellular Antiretroviral Concentrations in HIV-Infected Patients under Short Cycles of Antiretroviral Therapy. |
| Q91720332 | Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood |
| Q35826931 | Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients |
| Q99584374 | Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir |
| Q98178356 | Progress in the Research and Development of Anti-COVID-19 Drugs |
| Q35536588 | Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. |
| Q35147073 | Saquinavir: a review of its use in boosted regimens for treating HIV infection |
| Q46991286 | St. John's wort does not interfere with therapeutic drug monitoring of 12 commonly monitored drugs using immunoassays. |
| Q37598597 | Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults |
| Q103826033 | Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir |
| Q97636604 | The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic? |
| Q40199945 | The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients |
| Q35827755 | The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects |
| Q92117598 | The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event |
| Q90310442 | The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status |
| Q35187371 | Tipranavir |
| Q98771819 | Treatment Options for COVID-19: A Review |
| Q36261771 | Treatment of severe acute respiratory syndrome |
| Q42938439 | Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure |
| Q53382316 | Twenty years of therapy for HIV-1 infection. |
| Q28474772 | Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry |
| Q46929981 | Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra). |
| Q80130962 | [Approach to evaluating the clinical relevance of drug interactions in HIV-infected patients] |
| Q83887838 | [Cutaneous drug reactions in HIV-infected patients in the HAART era] |
| Q45942570 | [Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection]. |
Search more.